Circulation. Cardiovascular interventions
-
Circ Cardiovasc Interv · Dec 2012
Randomized Controlled TrialB-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial.
Contrast-induced acute kidney injury (CI-AKI) after percutaneous coronary intervention is associated with adverse short- and long-term outcomes. However, identification of patients at risk for CI-AKI is challenging. Using a large contemporary randomized trial database of patients with ST-segment-elevation myocardial infarction, we therefore sought to examine whether admission B-type natriuretic peptide (BNP) levels predict the development of CI-AKI. ⋯ URL: http://www.clinicaltrials.gov. Unique identifier: NCT00433966.
-
Circ Cardiovasc Interv · Oct 2012
Randomized Controlled TrialMentored simulation training improves procedural skills in cardiac catheterization: a randomized, controlled pilot study.
Despite valuable supplemental training resources for surgical skill acquisition, utility of virtual reality simulators to improve skills relevant to performing cardiac catheterization has not been evaluated. ⋯ Skills required to perform cardiac catheterization can be learned via mentored simulation training and are transferable to actual procedures in the catheterization laboratory. Less proficient operators derive greater benefit from simulator training than more proficient operators.
-
Circ Cardiovasc Interv · Oct 2012
Randomized Controlled Trial Meta AnalysisBivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
The optimal antithrombotic therapy for patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention is not well defined. We investigated the efficacy and safety of bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment. ⋯ URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00093158 and NCT00373451.
-
Circ Cardiovasc Interv · Oct 2012
Randomized Controlled Trial Comparative StudyPharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
High on-treatment platelet reactivity (HTPR) is associated with adverse outcomes. We aim to compare the novel thienopyridine prasugrel versus double-dose clopidogrel in patients with HTPR and explore the interaction between CYP2C19 genotype and both drugs. ⋯ URL: http://www.clinicaltrials.gov. Unique identifier: NCT01465828.
-
Circ Cardiovasc Interv · Jun 2012
Randomized Controlled Trial Multicenter Study Comparative StudyA randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
We evaluated the safety, efficacy, and tolerability of elinogrel, a competitive, reversible intravenous and oral P2Y(12) inhibitor that does not require metabolic activation, in patients undergoing nonurgent percutaneous coronary intervention. ⋯ URL: http://www.clinicaltrials.gov. Unique identifier: NCT00751231.